Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study

Patient-reported outcomes (PRO) are increasingly utilized as part of the routine clinical assessment in people with multiple sclerosis (pwMS). The long-term effect of disease modifying therapies (DMTs) and their discontinuation on PRO measures remains largely unknown.

Source: Journal of the Neurological Sciences - November 13, 2023 Category: Neurology Authors: Dejan Jakimovski, Katelyn S. Kavak, Karen Zakalik, Corey McGraw, Malcolm Gottesman, Patricia K. Coyle, Robert Zivadinov, Bianca Weinstock-Guttman, on behalf of New York State Multiple Sclerosis Consortium (NYSMSC) Source Type: research